267 related articles for article (PubMed ID: 33117345)
1. Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma.
Sabbatino F; Scognamiglio G; Liguori L; Marra A; Anniciello AM; Polcaro G; Dal Col J; Caputo A; Peluso AL; Botti G; Zeppa P; Ferrone S; Pepe S
Front Immunol; 2020; 11():561390. PubMed ID: 33117345
[TBL] [Abstract][Full Text] [Related]
2. Prognostic role of tumoral PDL1 expression and peritumoral FoxP3+ lymphocytes in vulvar melanomas.
Chłopik A; Selim MA; Peng Y; Wu CL; Tell-Marti G; Paral KM; Shalin SC; Kraft S; Hsu CK; Shea CR; Puig S; Fernandez-Figueras MT; Biernat W; Ryś J; Marszalek A; Hoang MP
Hum Pathol; 2018 Mar; 73():176-183. PubMed ID: 29307625
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of the tumor immune microenvironment in synovial sarcoma.
Oike N; Kawashima H; Ogose A; Hotta T; Hatano H; Ariizumi T; Sasaki T; Yamagishi T; Umezu H; Endo N
Cancer Sci; 2018 Oct; 109(10):3043-3054. PubMed ID: 30133055
[TBL] [Abstract][Full Text] [Related]
4. Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.
Kakavand H; Vilain RE; Wilmott JS; Burke H; Yearley JH; Thompson JF; Hersey P; Long GV; Scolyer RA
Mod Pathol; 2015 Dec; 28(12):1535-44. PubMed ID: 26403784
[TBL] [Abstract][Full Text] [Related]
5. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
6. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
Imai D; Yoshizumi T; Okano S; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Soejima Y; Aishima S; Oda Y; Maehara Y
Cancer Med; 2017 Jul; 6(7):1614-1626. PubMed ID: 28602029
[TBL] [Abstract][Full Text] [Related]
7. Combined Evaluation of Tumor-Infiltrating CD8 + and FoxP3 + Lymphocytes Provides Accurate Prognosis in Stage IA Lung Adenocarcinoma.
Kinoshita F; Takada K; Yamada Y; Oku Y; Kosai K; Ono Y; Tanaka K; Wakasu S; Oba T; Osoegawa A; Tagawa T; Shimokawa M; Oda Y; Mori M
Ann Surg Oncol; 2020 Jun; 27(6):2102-2109. PubMed ID: 31773516
[TBL] [Abstract][Full Text] [Related]
8. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.
Li F; Sun Y; Huang J; Xu W; Liu J; Yuan Z
Cancer Med; 2019 Dec; 8(17):7330-7344. PubMed ID: 31631566
[TBL] [Abstract][Full Text] [Related]
9. Tumor-infiltrating FoxP3+ Tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients.
Huang Y; Wang FM; Wang T; Wang YJ; Zhu ZY; Gao YT; Du Z
Digestion; 2012; 86(4):329-37. PubMed ID: 23207161
[TBL] [Abstract][Full Text] [Related]
10. Distribution pattern of tumor infiltrating lymphocytes and tumor microenvironment composition as prognostic indicators in anorectal malignant melanoma.
Kim SW; Kim YI; Mustafa B; Kim MJ; Jeong G; Ahn SM; Lim SB; Yu CS; Kim JC; Hong SM; Park IJ
Mod Pathol; 2021 Jan; 34(1):141-160. PubMed ID: 32709987
[TBL] [Abstract][Full Text] [Related]
11. A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer.
Flores-Martín JF; Perea F; Exposito-Ruiz M; Carretero FJ; Rodriguez T; Villamediana M; Ruiz-Cabello F; Garrido F; Cózar-Olmo JM; Aptsiauri N
Ann Surg Oncol; 2019 Aug; 26(8):2631-2639. PubMed ID: 31011905
[TBL] [Abstract][Full Text] [Related]
12. Tumor mutational load, CD8
Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
[TBL] [Abstract][Full Text] [Related]
13. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
[TBL] [Abstract][Full Text] [Related]
14. Nodular primary cutaneous melanoma is associated with PD-L1 expression.
Giavina-Bianchi M; Giavina-Bianchi P; Sotto MN; Rodig S; Mihm M; Festa Neto C; Duncan LM; Kalil J
Eur J Dermatol; 2020 Aug; 30(4):352-357. PubMed ID: 32969795
[TBL] [Abstract][Full Text] [Related]
15. Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain.
Herrera-Rios D; Mughal SS; Teuber-Hanselmann S; Pierscianek D; Sucker A; Jansen P; Schimming T; Klode J; Reifenberger J; Felsberg J; Keyvani K; Brors B; Sure U; Reifenberger G; Schadendorf D; Helfrich I
Front Immunol; 2020; 11():120. PubMed ID: 32117271
[TBL] [Abstract][Full Text] [Related]
16. Tumoral PD-L1 expression in desmoplastic melanoma is associated with depth of invasion, tumor-infiltrating CD8 cytotoxic lymphocytes and the mixed cytomorphological variant.
Frydenlund N; Leone D; Yang S; Hoang MP; Deng A; Hernandez-Perez M; Singh R; Biswas A; Yaar R; Mahalingam M
Mod Pathol; 2017 Mar; 30(3):357-369. PubMed ID: 28084337
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.
Koh J; Ock CY; Kim JW; Nam SK; Kwak Y; Yun S; Ahn SH; Park DJ; Kim HH; Kim WH; Lee HS
Oncotarget; 2017 Apr; 8(16):26356-26367. PubMed ID: 28412752
[TBL] [Abstract][Full Text] [Related]
18. Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients.
De Logu F; Galli F; Nassini R; Ugolini F; Simi S; Cossa M; Miracco C; Gianatti A; De Giorgi V; Rulli E; Cossu A; Massi D; Mandalà M
Cells; 2021 Feb; 10(2):. PubMed ID: 33671367
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer.
Morihiro T; Kuroda S; Kanaya N; Kakiuchi Y; Kubota T; Aoyama K; Tanaka T; Kikuchi S; Nagasaka T; Nishizaki M; Kagawa S; Tazawa H; Fujiwara T
Sci Rep; 2019 Mar; 9(1):4633. PubMed ID: 30874607
[TBL] [Abstract][Full Text] [Related]
20. Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome.
Garg K; Maurer M; Griss J; Brüggen MC; Wolf IH; Wagner C; Willi N; Mertz KD; Wagner SN
Hum Pathol; 2016 Aug; 54():157-64. PubMed ID: 27107457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
